Detail page

Knowledge Web

Person

Joachim Peter Steinbach (1966-)

Name	Joachim Peter Steinbach
Time	1966- (Date of birth and death)
Place	Tübingen (Geburtsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Variant	Joachim P. Steinbach J. P. Steinbach
Related	Universitätsklinikum Frankfurt
Further information	Habil. Fachgebiet Allgemeine Neurologie der Medizinischen Fakultät der Univ. Tübingen (2005); Diss. Univ. Tübingen (1993)
Record type	Person
GND-Identifier	113564813
Record ID	113564813
Involved in show all Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death An AMP‐activated protein kinase‐PGC‐1α axis mediates metabolic plasticity in glioblastoma Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations [P-06-05] A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression Modulation von Stammzellcharakteristika in Gliom-initiierenden Zellen durch GANT61 oder Arsentrioxid und (-)-Gossypol Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors MR imaging profile and histopathological characteristics of tumour vasculature, cell density and proliferation rate define two distinct growth patterns of human brain metastases from lung cancer AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial Bedeutung von SAMHD1 als Resistenzfaktor im humanen Neuroblastom Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization Molecular matched targeted therapies for primary brain tumors - a single center retrospective analysis Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter Pulmonary resection after radiosurgery and neoadjuvant immunochemotherapy for NSCLC patients with synchronous brain metastasis — a case series of three patients The acute superficial siderosis syndrome — clinical entity, imaging findings, and histopathology Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET : The Forschungszentrum Jülich Experience Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial Single-shot bevacizumab for cerebral radiation injury A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy A paravermal rtans-cerebellar approach to the posterior fossa tumor causes hypertrophic olivary degeneration by dentate nucleus injury Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy Matching quantitative MRI parameters with histological features of treatment-naïve IDH wild-type glioma Short-term fasting in glioma patients - analysis of diet diaries and metabolic parameters of the ERGO2 trial Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial Single-shot bevacizumab for cerebral radiation injury Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Activation of epidermal growth factor receptor sensitizes glioblastoma cells to hypoxia-induced cell death Cetuximab-mediated protection from hypoxia-induced cell death: implications for therapy sequence in colorectal cancer Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma Maintenance of energy homeostasis during calorically restricted ketogenic diet and fasting-MR-spectroscopic insights from the ERGO2 trial Non-invasive measurement of drug and 2-HG signals using 19F and 1H MR spectroscopy in brain tumors treated with the mutant IDH1 inhibitor BAY1436032 Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab Car-engineered nk cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy Delayed occurrence of hypertrophic olivary degeneration after therapy of posterior fossa tumors: A single institution retrospective analysis Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas EGFR and mTOR as therapeutic targets in glioblastoma Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients Second generation mtor inhibitors as a double-edged sword in malignant glioma treatment

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Joachim Peter Steinbach (1966-)

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death

An AMP‐activated protein kinase‐PGC‐1α axis mediates metabolic plasticity in glioblastoma

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas

Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat

Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations

[P-06-05] A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression

Modulation von Stammzellcharakteristika in Gliom-initiierenden Zellen durch GANT61 oder Arsentrioxid und (-)-Gossypol

Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment

High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors

MR imaging profile and histopathological characteristics of tumour vasculature, cell density and proliferation rate define two distinct growth patterns of human brain metastases from lung cancer

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

Bedeutung von SAMHD1 als Resistenzfaktor im humanen Neuroblastom

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management

DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis

DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment

Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization

Molecular matched targeted therapies for primary brain tumors - a single center retrospective analysis

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Pulmonary resection after radiosurgery and neoadjuvant immunochemotherapy for NSCLC patients with synchronous brain metastasis — a case series of three patients

The acute superficial siderosis syndrome — clinical entity, imaging findings, and histopathology

Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET : The Forschungszentrum Jülich Experience

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Single-shot bevacizumab for cerebral radiation injury

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

A paravermal rtans-cerebellar approach to the posterior fossa tumor causes hypertrophic olivary degeneration by dentate nucleus injury

Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide

Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy

Matching quantitative MRI parameters with histological features of treatment-naïve IDH wild-type glioma

Short-term fasting in glioma patients - analysis of diet diaries and metabolic parameters of the ERGO2 trial

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Single-shot bevacizumab for cerebral radiation injury

Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

Activation of epidermal growth factor receptor sensitizes glioblastoma cells to hypoxia-induced cell death

Cetuximab-mediated protection from hypoxia-induced cell death: implications for therapy sequence in colorectal cancer

Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma

Maintenance of energy homeostasis during calorically restricted ketogenic diet and fasting-MR-spectroscopic insights from the ERGO2 trial

Non-invasive measurement of drug and 2-HG signals using 19F and 1H MR spectroscopy in brain tumors treated with the mutant IDH1 inhibitor BAY1436032

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients

Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab

Car-engineered nk cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy

Delayed occurrence of hypertrophic olivary degeneration after therapy of posterior fossa tumors: A single institution retrospective analysis

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas

EGFR and mTOR as therapeutic targets in glioblastoma

Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide

Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients

Second generation mtor inhibitors as a double-edged sword in malignant glioma treatment